Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
CA 2106492 C · Owner: Garcon-Johnson, Nathalie Marie-Josephe · Inventors: Francotte, Myriam; Prieels, Jean-Paul; Slaoui, Moncef
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a vaccine formulation comprising a Herpes simplex virus (HSV), glycoprotein D or an immunological fragment thereof effective in inducing protective, immunity in conjunction with 3-o-deacylated monophosphoryl lipid A and a suitable, carrier. The vaccine formulation is useful for prophylaxis or treatment of Herpes, simplex virus infections.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 1992 and granted December 9, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 17, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.